search
Back to results

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Primary Purpose

Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Vincristine
Prednisone
Doxorubicin
Etoposide
Pomalidomide
Cyclophosphamide
Rituximab
Sponsored by
National Cancer Institute (NCI)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diffuse Large Cell Lymphoma focused on measuring Non-Hodgkin Lymphoma, Epstein Barr Virus, Plasmablastic Lymphoma, Chemotherapy, Immune Modulatory

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers
  • INCLUSION CRITERIA:
  • Participants must have histologically or cytologically confirmed B-cell non-Hodgkin lymphoma confirmed by the Laboratory of Pathology, NCI, with one or more of the following features:

    • Leptomeningeal/CSF involvement
    • High-risk for CNS relapse per CNS-IPI (score 4-6)
    • Plasmablastic histology
    • Gammaherpesvirus positive tumor
    • Presence of Kaposi sarcoma
  • Measurable or evaluable lymphoma.
  • Positive HIV1/2 serology.
  • Participants may not have received prior curative-intent chemotherapy for lymphoma.
  • Participants who have received prior treatment as a bridge to curative-intent therapy will be considered per Protocol Chair discretion if >= 2 weeks since administration.
  • Age >=18 years
  • ECOG performance status <=4
  • Persons of childbearing potential (PCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 14 days prior to and again within 1 day before starting pomalidomide and must either commit to continued abstinence from penetrative vaginal intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before the participant starts taking pomalidomide and for 28 days after the last dose of pomalidomide.
  • All study participants must agree to be registered into the mandatory POMALYST REMS[Registered]TM program and be willing and able to comply with the requirements of the POMALYST REMS[Registered]TM program.
  • Able to take aspirin 81mg orally daily or another substitute thromboprophylaxis.
  • Participants must have adequate organ and marrow function as defined below unless abnormalities are attributed to lymphoma or HIV as determined by investigator:

    • absolute neutrophil count >=1,000/mcL
    • platelets >=75,000/mcL
    • total bilirubin <=1.5 X institutional upper limit of normal (participants with history of Gilbert disease are eligible if total bilirubin <= 5 mg/dL with <80% unconjugated bilirubin)
    • AST(SGOT)/ALT(SGPT) <=3 X institutional upper limit of normal
    • creatinine clearance >=60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal.
  • Participants with hepatitis B virus (HBV) infection must be on suppressive antiviral therapy.
  • Participants must be willing to take and adhere to antiretroviral therapy (participants are not required to be on any specific regimen of antiretroviral therapy).
  • Participants must understand and sign a written informed consent document.

EXCLUSION CRITERIA:

  • Participants who are receiving any other investigational agents.
  • Participants requiring any of the agents listed as prohibited thearapies.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to pomalidomide or other agents used in study.
  • Parenchymal brain involvement with lymphoma.
  • Ejection fraction less than 40% by echocardiography (ECHO)
  • CTCAEv5.0 Grade 3-4 neuropathy
  • History of malignant tumors other than Kaposi sarcoma or KSHV-associated multicentric Castleman Disease, unless:

    • In complete remission for >= 1 year from the time response was first documented; or,
    • Completely resected basal cell carcinoma; or,
    • In situ squamous cell carcinoma of the cervix or anus; or,
    • Prior or concurrent malignancy has a natural history or treatment which does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen per Protocol Chair discretion.
  • Known drug-related, inherited, or acquired procoagulant disorder including prothrombin gene mutation 20210, antithrombin III deficiency, protein C deficiency, protein S deficiency and antiphospholipid syndrome but not including heterozygosity for the Factor V Leiden mutation or the presence of a lupus anticoagulant in the absence of other criteria for the antiphospholipid syndrome.
  • Symptomatic congestive heart failure
  • Unstable angina pectoris, or cardiac arrhythmia.
  • Uncontrolled intercurrent illness or participants considered to be of poor medical health due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active uncontrolled infection (excluding lymphoma or HIV) as documented in prior records or suggested by medical history, physical examination or standard clinical assessments such as imaging and laboratory studies.
  • Pregnant or breast-feeding persons (if lactating, must agree not to breast feed while taking pomalidomide).

Sites / Locations

  • National Institutes of Health Clinical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

1/Dose Escalation

2/Dose Expansion

Arm Description

Pomalidomide (escalating doses) + Prednisone, Etoposide, Doxorubicin, Vincristin

Pomalidomide (at the MTD) + Prednisone, Etoposide, Doxorubicin, Vincristine and

Outcomes

Primary Outcome Measures

safety and tolerability
The fraction of patients with toxicity noted at each dose level will be reported by grade and type of toxicity identified. Maximum tolerated dose will also be reported.

Secondary Outcome Measures

progression-free survival
duration of time from the start of the treatment until time of disease relapse from PR, disease progression, or death, whichever occurs first
preliminary estimates of response
Percentage of participants with the best overall response of CR or PR to therapy

Full Information

First Posted
May 21, 2022
Last Updated
September 16, 2023
Sponsor
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT05389423
Brief Title
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Official Title
Phase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Study Type
Interventional

2. Study Status

Record Verification Date
September 15, 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 27, 2023 (Actual)
Primary Completion Date
June 1, 2028 (Anticipated)
Study Completion Date
June 1, 2032 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Cancer Institute (NCI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV in the United States. People with HIV are up to 17 times more likely to get NHL than people who do not have HIV. The disease may also be different in these two groups. More study is needed for treating people with both HIV and NHL. Objective: To test a study drug (pomalidomide) in combination with chemotherapy with or without another drug (rituximab) in people with HIV-associated NHL. Eligibility: Adults aged 18 years or older diagnosed with HIV-associated B-cell NHL with high-risk features. Design: Participants will undergo screening. They will have a physical exam. They will have blood and urine tests and tests of heart function. They may have imaging scans. Researchers will review tissue samples of participant s tumors. In some cases, a new biopsy may be needed. Participants will receive up to 6 cycles of treatment. The first cycle is 26 days: Participants will take pomalidomide by mouth for 10 days. After 5 days they will start receiving chemotherapy drugs through a tube attached to a needle placed in a vein (IV). Some participants will receive rituximab on day 5. All participants will receive a second set of IV drugs that will last for 4 days (96 hours). They will receive another IV drug after the previous treatment is complete. The remaining cycles are each 21 days. Participants will take pomalidomide by mouth for the first 10 days. Other chemotherapy treatments will also be repeated starting on day 1 of each cycle. Screening tests will be repeated at study visits. Follow-up visits will continue for 4 years.
Detailed Description
Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV (PLWH) in the United States. Even in the modern era of antiretroviral therapy (ART), PLWH have an 11- to 17-fold higher risk of NHL than the general population due in part to CD4+ T-cell lymphopenia but also immune dysregulation and exhaustion from chronic viral antigen stimulation. The most common NHL subtypes are diffuse large cell lymphoma (DLBCL) and Burkitt lymphoma (BL), that are much more frequently associated with the oncogenic virus Epstein Barr virus (EBV) in PLWH, which portends a poorer prognosis, than in the general population. Plasmablastic lymphoma (PBL) is a rare CD20 negative B cell lymphoma associated with EBV almost exclusively seen in PLWH. Although these subtypes of lymphoma occur in the general population, their presentation and pathogenesis may be different - meaning there may be different therapeutic targets and strategies to consider in HIV-associated lymphomas necessitating clinical trials targeted to this underserved population of patients. Lenalidomide, a 2nd generation immunomodulatory drug, has shown safety and improved survival in combination with chemotherapy in advanced stage DLBCL in one of two randomized trials. Pomalidomide, a 3rd generation immunomodulatory agent, has activity in primary CNS lymphoma demonstrating its activity in both NHL and CNS involvement, which is more common in PLWH and NHL. In a number of parameters, it is more potent than lenalidomide. Pomalidomide has shown to increase NK and T-cell activation and reverse T-cell senescence in addition to increasing CD4+ T-cell count in PLWH and cancer. It can also enhance expression of surface immune markers in vitro in cell lines from EBV-induced tumors. -Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) along with rituximab (DA-EPOCH-R) is an anthracycline-based regimen that has been shown to be safe and effective in PLWH and in the most common subtypes of NHL seen in PLWH, DLBCL and BL. Objective: -Determine the safety and maximum tolerated dose (MTD) of the combination of pomalidomide and dose-adjusted EPOCH +/ rituximab (DA-EPOCH-RP) in participants with enrolled subtypes of HIV-associated lymphomas Eligibility: Adult participants >= 18 years with pathology-confirmed HIV-associated B-cell non-Hodgkin lymphoma with high-risk features, excluding primary CNS lymphoma Positive HIV1/2 serology Design: -This is a phase 1 study of pomalidomide in combination with DA-EPOCH +/- Rituximab (DA-EPOCH-RP) in participants with HIV-associated B-cell non-Hodgkin lymphoma. Only participants with CD20+ HIV-associated B-cell non-Hodgkin lymphoma will receive Rituximab. This is a dose escalation study to evaluate pomalidomide in combination with modified DA-EPOCH-R to determine safety and tolerability. Dosing will begin at dose level 1, 3 mg of pomalidomide and proceed to dose escalation or de-escalation to doses 4 mg or 2 mg depending on dose-limiting toxicities. Participants will be prescribed antiretroviral therapy (ART). In this phase I study, up to 12 evaluable participants will be accrued in the escalation phase (3-6 participants per level) and up to 6 evaluable participants will be accrued in the expansion phase to be treated at MTD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, Plasmablastic Lymphoma, B-Cell Neoplasm
Keywords
Non-Hodgkin Lymphoma, Epstein Barr Virus, Plasmablastic Lymphoma, Chemotherapy, Immune Modulatory

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1/Dose Escalation
Arm Type
Experimental
Arm Description
Pomalidomide (escalating doses) + Prednisone, Etoposide, Doxorubicin, Vincristin
Arm Title
2/Dose Expansion
Arm Type
Experimental
Arm Description
Pomalidomide (at the MTD) + Prednisone, Etoposide, Doxorubicin, Vincristine and
Intervention Type
Drug
Intervention Name(s)
Vincristine
Intervention Description
0.4 mg/m2/day administered by CIVI on days 1 to 4
Intervention Type
Drug
Intervention Name(s)
Prednisone
Intervention Description
60 mg/m2/day administered orally on days 1 to 5
Intervention Type
Drug
Intervention Name(s)
Doxorubicin
Intervention Description
10 mg/m2/day administered by CIVI on days 1 to 4
Intervention Type
Drug
Intervention Name(s)
Etoposide
Intervention Description
50 mg/m2/day administered by CIVI on days 1 to 4
Intervention Type
Drug
Intervention Name(s)
Pomalidomide
Intervention Description
An initial dose of 3mg administered orally for 10 days in all cycles. In cycle 1, it will start 5 days before DA-EPOCH; in cycles 2-6, it will start on day 1. Administered at an MTD dose for the expansion phase.
Intervention Type
Drug
Intervention Name(s)
Cyclophosphamide
Intervention Description
750 mg/m2 administered IV on day 5
Intervention Type
Drug
Intervention Name(s)
Rituximab
Intervention Description
375 mg/m2 administered IV on day 1 (only for CD20+ tumors)
Primary Outcome Measure Information:
Title
safety and tolerability
Description
The fraction of patients with toxicity noted at each dose level will be reported by grade and type of toxicity identified. Maximum tolerated dose will also be reported.
Time Frame
6 cycles of treatment, or until confirmed progression, unacceptable toxicity or trial withdrawal
Secondary Outcome Measure Information:
Title
progression-free survival
Description
duration of time from the start of the treatment until time of disease relapse from PR, disease progression, or death, whichever occurs first
Time Frame
every 3 weeks for the first 6 cycles, every 3 months for the rest of the first year, then every 6 months for 4 years (5 years total).
Title
preliminary estimates of response
Description
Percentage of participants with the best overall response of CR or PR to therapy
Time Frame
every 3 weeks for the first 6 cycles, every 3 months for the rest of the first year, then every 6 months for 4 years (5 years total).

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
INCLUSION CRITERIA: Participants must have histologically or cytologically confirmed B-cell non-Hodgkin lymphoma confirmed by the Laboratory of Pathology, NCI, with one or more of the following features: Leptomeningeal/CSF involvement High-risk for CNS relapse per CNS-IPI (score 4-6) Plasmablastic histology Gammaherpesvirus positive tumor Presence of Kaposi sarcoma Measurable or evaluable lymphoma. Positive HIV1/2 serology. Participants may not have received prior curative-intent chemotherapy for lymphoma. Participants who have received prior treatment as a bridge to curative-intent therapy will be considered per Protocol Chair discretion if >= 2 weeks since administration. Steroids given for any reason or rituximab given for multicentric Castleman disease may be given any time prior to treatment start. Age >=18 years ECOG performance status <=4 Persons of childbearing potential (PCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 14 days prior to and again within 1 day before starting pomalidomide and must either commit to continued abstinence from penetrative vaginal intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before the participant starts taking pomalidomide and for 28 days after the last dose of pomalidomide. All study participants must agree to be registered into the mandatory POMALYST REMS[Registered]TM program and be willing and able to comply with the requirements of the POMALYST REMS[Registered]TM program. Able to take aspirin 81mg orally daily or another substitute thromboprophylaxis. Participants must have adequate organ and marrow function as defined below unless abnormalities are attributed to lymphoma or HIV as determined by investigator: absolute neutrophil count >=1,000/mcL platelets >=75,000/mcL total bilirubin <=1.5 X institutional upper limit of normal (participants with history of Gilbert disease are eligible if total bilirubin <= 5 mg/dL with <80% unconjugated bilirubin) AST(SGOT)/ALT(SGPT) <=3 X institutional upper limit of normal creatinine clearance >=60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal. Participants with hepatitis B virus (HBV) infection must be on suppressive antiviral therapy. Participants must be willing to take and adhere to antiretroviral therapy (participants are not required to be on any specific regimen of antiretroviral therapy). Participants must understand and sign a written informed consent document. EXCLUSION CRITERIA: Participants may not receive investigational agents on other clinical trials. Participants requiring any of the agents listed as prohibited thearapies. History of allergic reactions attributed to compounds of similar chemical or biologic composition to pomalidomide or other agents used in study. Parenchymal brain involvement with lymphoma. Ejection fraction less than 40% by echocardiography (ECHO) CTCAEv5.0 Grade 3-4 neuropathy History of malignant tumors other than Kaposi sarcoma or KSHV-associated multicentric Castleman Disease, unless: In complete remission for >= 1 year from the time response was first documented; or, Completely resected basal cell carcinoma; or, In situ squamous cell carcinoma of the cervix or anus; or, Prior or concurrent malignancy has a natural history or treatment which does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen per Protocol Chair discretion. Known drug-related, inherited, or acquired procoagulant disorder including prothrombin gene mutation 20210, antithrombin III deficiency, protein C deficiency, protein S deficiency and antiphospholipid syndrome but not including heterozygosity for the Factor V Leiden mutation or the presence of a lupus anticoagulant in the absence of other criteria for the antiphospholipid syndrome. Symptomatic congestive heart failure Unstable angina pectoris, or cardiac arrhythmia. Uncontrolled intercurrent illness or participants considered to be of poor medical health due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active uncontrolled infection (excluding lymphoma or HIV) as documented in prior records or suggested by medical history, physical examination or standard clinical assessments such as imaging and laboratory studies. Pregnant or breast-feeding persons (if lactating, must agree not to breast feed while taking pomalidomide).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anaida Widell
Phone
(240) 760-6074
Email
anaida.widell@nih.gov
First Name & Middle Initial & Last Name or Official Title & Degree
Kathryn A Lurain, M.D.
Phone
(301) 250-5156
Email
kathryn.lurain@nih.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kathryn A Lurain, M.D.
Organizational Affiliation
National Cancer Institute (NCI)
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Institutes of Health Clinical Center
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20892
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
For more information at the NIH Clinical Center contact National Cancer Institute Referral Office
Phone
888-624-1937

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
. All IPD recorded in the medical record will be shared with intramural investigators upon request.
IPD Sharing Time Frame
Clinical data available during the study and indefinitely.
IPD Sharing Access Criteria
Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.
Links:
URL
https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_000274-C.html
Description
NIH Clinical Center Detailed Web Page

Learn more about this trial

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

We'll reach out to this number within 24 hrs